Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of EluciremTM (Gadopiclenol) Injection for Use in Contrast-Enhanced MRI

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of EluciremTM (Gadopiclenol) Injection for Use in Contrast-Enhanced MRI

Read the press release
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

Read the press release
Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol 

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol 

Read the Announcement
Helping You Reach Your Targets ​with a Cutting-Edge Portfolio

​Expanding Embolization Procedures

Helping You Reach Your Targets ​with a Cutting-Edge Portfolio

Digital launch
12 March 2022

Take a tour and book your seat
821Alexander Exterior1

Proudly serving the US healthcare market

Guerbet has become one of the leading experts in medical imaging worldwide. Collectively, we offer a full range of medical solutions and services in diagnostic imaging and interventional imaging.

Learn more about Guerbet

Discover the Latest News of Guerbet North America

JH C1 Graphic

Jared Houk, Guerbet North America’s Commercial VP discusses evolution of Medical Imaging

Read the full interview
Optistar C1

Top Medical Imaging Company and Provider of Diagnostic Imaging Collaborate to Elevate Patient Experience and Lower Cost of Care

Read the press release

Announcements

Guerbet 2021 Funded Grantee3 (003)
Guerbet Announces Key Research and Educational Grants and Partnerships Read more
D3guerbet 02 21 Neuro Figure01a

Applied Radiology Conducts Dotarem Case Studies

Learn more